BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Deargen

Deargen logo

Founded
2016
Geography
South Korea based
Funding
$2.630 M

DEARGEN advances the treatment of rare and intractable diseases through the integration of AI and collective intelligence.
Dr. UG is an AI platform for developing new drugs that is based on DEARGEN’s deep learning technology.
It specializes in genome data analysis, biomarker prediction, molecule selection and optimization.
DEARGEN discovers new disease targets with Dr.UG and further realizes precision medicine by designing small molecules for new drugs.


drug discovery

Technologies

AI Companies (Drug Discovery)   Pharmaceutical and Drug Discovery  

R&D Platform

The 4D (Deargen-Driven Drug Development) program is a new drug development pipeline led by Deargen from the discovery of Hit substances.
Using A.I, we develop optimal new drug candidates through the iterative process of prediction, synthesis, validation, and re-learning.


Dr.UG

Read more

Pipelines

None
Preclinical  |  Visit website

DEARGEN has long been establishing an AI-based new drug development process
through operating a cooperative network with experts in new drug development.
Our innovative new drug pipeline will allow the radical cure of diseases that have remained difficult to treat.

1. ALS
2. Colorectal cancer
3. AI-Protac
4. Sarcopenia

Products

 

Services

No services posted yet